Purpose: In spite of rapidly growing interest, few research tools have been developed to study female sexual dysfunction. Using the D 1 /D 2 agonist, apomorphine (APO), our objective was to develop a new model of the sexual arousal response in female rats based on one previously established for the male condition. Methods: APO (80 lg/kg, s.c.) was given during proestrus (P), estrus (E), metestrus (M), early diestrus (DI) and late diestrus (DII), and in ovariectomized (OVX) female Wistar rats. APO-induced behavioral and genital responses were characterized (30 min) using video monitoring. Results: APO-induced reproducible, periodic morphological changes in the external genitalia. The onset, timing and duration of these female APO responses were consistent with genital vasocongestive arousal (GVA) responses in males (ie erections). APO-induced GVAs occurred throughout the estrous cycle, peaking in E (1.4 7 1.21 overall; 0.9 7 0.64 in DII; 1.8 7 1.66 in E) and were markedly diminished by ovariectomy (OVX, 0.4 7 0.51). Conclusion: APO induced a reproducible sexual arousal response in female rats involving obvious genital vasocongestive engorgement. Further, the findings demonstrate that the APO-induced genital arousal responses are hormonally regulated.
Introduction
Female sexual function is a field undergoing rapid exploration yet the physiological and psychological mechanisms involved remain largely unresolved. Similar to previous research in male erectile function and dysfunction, the need for developing animal models in order to study basic physiology, pathophysiology, and possible treatments of female sexual dysfunction (FSD) has become increasingly important.
FSD is classified as a condition in which there are alterations in the processes involved in the female sexual response cycle or by pain associated with sexual intercourse. 1 FSD can be categorized into four main areas: (1) sexual desire disorders, namely hypoactive sexual desire or sexual aversion disorder, (2) sexual arousal disorders, (3) orgasmic disorders, and (4) sexual pain disorders that include dyspaureunia and vaginismus. 2 Recent studies suggest that at least 30% 3 of women suffer with some form of difficulty.
A major subcategory of FSD is female sexual arousal disorder (FSAD). Female sexual arousal results in a series of vasocongestive and lubricative events resulting primarily from increased blood flow to clitoral, labial, and vaginal tissue. 1, 4 This increased blood flow to the genital area is similar to the male sexual response of the erection. Peripheral innervation of the female genital tract occurs via central-peripheral neural connections that are anatomically similar to those found in the male. 5 At the level of the female genitalia it appears that the sympathetic, parasympathetic, and nonadrenergic noncholinergic (NANC) systems are responsible for the primary neural regulation of blood flow. Although implicated, the precise contribution (facilitatory/inhibitory) of the cholinergic (parasympathetic), adrenergic (sympathetic), and NANC (nitric oxide (NO), vasoactive intestinal peptide, calcitonin gene-related peptide) systems to the vascular responses has not been elucidated. and hormonal disorders. 10 Unfortunately, addressing these problems therapeutically has met with less success than had been hoped. For example, treatments that are successful in treating male erectile dysfunction (MED), such as sildenafil, have shown variable success in ameliorating FSAD. 11 It may be that a different spectrum of activities is needed when devising treatments for women, such as changing the dose of drug, duration of action, and time course of delivery. In particular, an understanding of the hormonal variations throughout the reproductive cycle in females must be factored when developing possible therapeutics. In contrast, short-term variations in hormonal milieu are not a major factor in the male sexual response to therapy, as testosterone levels remain stable over weeks or months.
Clinical and basic research in MED has been extensive. In basic research there has been a very important role for investigations involving animal models. Attempts to develop conscious animal models of the female sexual response have, for the most part, been limited to behavioral paradigms. A common approach in previous studies has been the assessment of female sexual receptivity based on a surrogate marker, lordotic posturing, 12 in relation to male copulatory contact. [12] [13] [14] The problem with this approach is that in other studies components of these behavioral responses have persisted despite lesioning of the hypothalamus 15 Fa key central site for initiation of neurogenic sexual signalling. 16, 17 Furthermore, the definition of this female behavioral response does not require there to be a specific genital manifestation (ie vasocongestive arousal). In fact, it may be that sexual dysfunction, occurring at the level of the pudendal vasculature, may not even be detected using these behavioral paradigms alone. More recent methods have been established that can specifically assess increases in blood flow to vaginal and clitoral tissues following nerve stimulation in anesthetized animals. 8, 18 However, a limitation of these approaches is that in having to use anaesthetized animals the associated behavioral and physiological components of the sexual responses cannot be measured.
The erection is the obvious, standard sexual arousal response in the male. In this regard, the apomorphine (APO)-induced bioassay of erectile function in the male rat 19 is an established animal model of this component of the sexual response. APO elicits erections by acting primarily on dopamine type 2 (D 2 ) receptors in the paraventricular nucleus of the hypothalamus. 20 The objective of the present study was to characterize both the behavioral and genital morphological changes that occur in the female rat following APO administration. In addition, by comparing the components of the APOinduced response in female rat to the APO response in males, a better understanding of sexual arousal in the female rat can be achieved. Finally, by administering APO at different points in the estrous cycle and in ovariectomized (OVX) animals the effect of different hormonal conditions on APO-induced sexual response can be determined.
Methods and materials

Animals
Eight adult female Wistar rats (225-250 g) obtained from the Charles River Laboratories (Montreal, Canada) were used for the purpose of this study. Animals were housed in polypropylene shoebox cages in a climate-controlled room with a 12/12-h light/dark cycle. Food (Purina rat chow s ) and water were provided ad libitum except during times of testing. The procedures carried out in this study were in accordance with the Canadian Council of Animal care. Rats were handled for 5 consecutive days prior to experimentation to allow for acclimation to the investigator. Prior to experimentation, all rats showed a consistent 4-day estrous cycle consisting of normal periods of proestrus (P), estrus (E), metestrus (M) and diestrus (D).
Experimental procedure
A modification of a previous protocol using APO (80 mg/kg in 100 mg/ml ascorbic acid in water, s.c.) was used. 19 In preliminary studies, a dose-response assessment (APOF40, 80, 120 mg/kg) demonstrated that a dose of 80 mg/kg APO, similar to the male, elicited the greatest number of genital grooming responses in the female rat. Rats were placed in hanging cages with bottoms constructed of Plexiglas s , in a dark, quiet room where they were allowed to acclimate for 10 min before the testing period. Following APO administration, the number of genital responses and associated yawning responses were recorded for a 30 min period via a video monitoring system in an adjacent room. A genital response was counted when there was a distinct change in the appearance of the external genitalia accompanied by oral grooming of this region. A yawn was counted as an involuntary opening of the mouth with the associated respiratory movement.
Vaginal smears
The characteristics of the cells contained in vaginal smears from each rat were determined under a light microscope to establish the stage of the estrous 
Experiment AFAPO-induced responses in intact rats
APO-induced genital responses and yawning responses were determined during each stage of the E cycleFP (B12 h), E (B12 h), M (B21 h), D (total of B57 h). 22 DI was considered to be the first half and DII the second half of this segment of the E cycle.
Experiment BFAPO-induced responses in OVX rats
The APO responses were determined in OVX 24 rats to determine the effect of decreasing the levels of endogenous hormones. In brief, animals were anesthetized with isoflurane gas delivered via a Bain rebreathing system. Using a dorsal approach, a small transverse incision was made 1.5 cm from the spine (over the ovaries), approximately half-way between the middle of the back and the base of the tail. Both ovaries were removed by ligating and severing the junction between the fallopian tube and uterine horn. Postoperative analgesia (buprenorphine, Buprenext, 0.05 mg/kg) and antibiotics (0.1 ml/100 g body wt., Tribrissent 24%, Schering Canada Inc.) were administered daily for 5 days. Animals were given at least 1 week to recover before the onset of experimentation.
Data analysis
Statistical analysis of the genital responsesFbetween (1) APO-treated and saline control groups and (2) intact and OVX groups to determine statistical differenceFwas performed using Mann-Whitney rank sum test (Po0.05). In addition, to assess the different stages of the estrous cycle within each treatment group (APO, saline) a Friedman repeated measures ANOVA on ranks was performed. Differences in the yawn response between APO-treated intact and OVX groups were determined using Student's t-test (Po0.05) and differences between stages of the estrous cycle was performed using oneway repeated measures ANOVA and posthoc, Neuman-Keuls for comparison of means.
Results
APO-induced behavioral and genital responses
In each rat administered APO (80 mg/kg, s.c.), preceding the genital responses, there was a patterned behavioral response that was initiated by a 'startle' response, in which the awareness of the rat to its surroundings appears suddenly heightened. This is followed by a movement causing concavity of the back followed by the animal rearing onto their hind legs. In most instances, the overall response was completed by a genital grooming response, in which the head rapidly descends towards the genital area, immediately following the initial rearing.
More importantly, APO administration induced a distinct change in the morphology of the external genitalia of the female rat. This genital response ( Figure 1, lower panel) , similar to the genital vasocongestive arousal (GVA) seen in males, was characterized by significant engorgement (ie swelling of tissue surrounding the vagina as well as increased dimensions of the introitus that lasted 2-3 s). The predominant mechanism of the GVA is most likely neurovascular, since there are no other known physiological mechanisms/processes that could account for the rapid time course and properties of the observed change. It is important to recognize that, similar to the spontaneous erectile responses in male rats, female rats also normally exhibit a low frequency of GVA responses without APO administration (incidence rate o0.2 spontaneous GVAs per 30 min period following saline).
In addition, genital grooming occurred in some rats without any of the accompanying genital or patterned behavioral responses (non-GVA) (Figure 1,  upper panel) . This non-GVA response was seen in both control and APO tested animals, and was not related to the specific sexually or hormonally based responses.
Time course of APO responses in intact rats
APO was administered to eight female Wistar rats (250-275 g) in each stage of the estrous cycle, as defined by vaginal smearing assessments, and the number of responses was counted in the subsequent 30 min. The average number of responses in each stage was calculated.
APO produced a significant enhancement (Po0.05) in the average number of GVA responses in every segment of the estrous cycle, although the data revealed that the peak response rate occurred during estrus. In contrast, non-GVA responses were similar across the cycle in both APO and control animals ( Figure 2, middle panel) . Further, corre- Cumulative GVA responses in APO-treated rats, during all stages of the estrous cycles, was almost 20 times as frequent as in controls (Figure 2, lower) , whereas there were no differences in non-GVA responses (Figure 2 lower) . The time course distribution of APO-induced GVA responses over the 30-min period showed that GVA responses peaked in the 5-10 time interval, with 80% of total GVA responses occurring within the first 20 min time period (Figure 3, upper panel) . The pattern of APOinduced yawning responses showed a peak during the 15-20 min interval (Figure 3, lower panel) .
GVA responses in OVX rats
GVA responses were determined in eight Wistar rats following OVX and the number of APO-induced responses assessed at least 1 week after surgery.
There was a significant decrease in APO-induced GVA responses observed in OVX versus intact of approximately 80% (Figure 4, upper panel) . There was no significant difference in non-GVA responses between OVX versus intact animals in both APOtested animals and vehicle administration (Figure 4 , upper panel and lower panel). APO-induced yawns were observed in both OVX and intact animals ( Figure 4, lower panel) .
Discussion
The major finding in this study, using conscious female rats, is that administration of low doses of APO induces reproducible behavioral and genital responses that are dependent on hormonal milieu. Specifically, the temporal pattern and characteristics of the genital responses (GVAs) were analogous to the APO-induced GVA (ie erection) response in the male rat. 20 As in the male, APO-induced yawns in female rats were also observed but were not temporally associated with the behavioral or genital events. Figure 1 Time course of genital grooming response in intact female rats. During a typical grooming response there is no change in the morphology of the external genitalia (top). During an APO-induced sexual arousal response (bottom) there is a rapid and distinct engorgement of the genitalia (within 3 s) indicative of GVA.
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The present findings in female rats provide strong evidence that the patterned behavioral and genital responses following APO administration are a likely consequence of the known hypothalamic actions of this dopamine mimetic agent on this sexual response centers. 19, 25, 26 Consistent with this observation, APO has previously been shown to enhance lordosis behavior in female rats. 13, 20, 27 Further, previous findings have demonstrated that this low dose of APO does not produce systemic changes in the circulation in male rats, that is there are no changes in arterial pressure (unpublished observations).
In the present study, the time course of the APOinduced engorgement of the external genitalia and widening of the introitus 6 occurred over a 2-3 s interval. Thus, in both male and female rats, APO can induce genital changes that are rapid in onset, transient in nature, and involve a similar coordination of behavioral and genital responses. 19 Specifically, in both, the patterned behavioral response includes a 'startle' response, movements including rearing, head descent, and genital grooming.
The erectile response in male rats is known to be hormonally dependent, given that erections are markedly reduced following castration and are restored with testosterone supplementation. 28, 29 Similarly, in the present investigation the magnitude of the APO-induced response in female rats appears to be hormonally regulated based on the variation in the response during the estrous cycle. Rat model of female sexual arousal RKS Beharry et al
The peak of the APO-induced GVA responses, similar to the natural sexual receptivity, during P and E, and subsequent decline during late DII, 30, 31 parallels the pattern of action of estrogen and progesterone. 32, 33 Furthermore, the finding that APO-induced GVA responses were markedly diminished following OVX confirmed this hormonal dependency in female rats. It is interesting that both central and peripheral nervous system mechanisms promoting the sexual arousal response, including both NANC nerve release of NO and vasoactive intestinal peptide (VIP), are hormonally regulated. 1, 34, 35 Previous assessments of sexual responses, particularly in female animals, have focused on behavioral responses as opposed to physiological mechanisms at the level of the genitalia. [12] [13] [14] Recently, models using anesthetized female rabbits and rats have also been developed to characterize the physiology and pathophysiology of vasculogenic female sexual function and dysfunction, respectively. 6, 8, 18, 36, 37 For the most part, these studies have focussed on mechanisms involved in the impairment of vaginal vasocongestive responses and the production of a clitoral erectile responses. 6, 8 In conclusion, based on a review of the literature, it appears that the present development of a female animal model, incorporating central initiation and peripheral genital responses, is the first of its type. Specifically, the findings indicate that low-dose APO initiates GVA responses in female rats in a hormonally dependent manner. This model will likely have immediate utility in helping to elucidate mechanisms involved in female sexual function and dysfunction. Rat model of female sexual arousal RKS Beharry et al
